Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study
References
- 1. M.E. LACOUTURE.
Importance of dermatological care for patients with cancer, The Asco Post, 2012,http://www.ascopost.com/issues/september-15-2012/importance-of-dermatologic-care-for-patients-with-cancer/ [accessed December 2017]. - 2. CHMIELOWSKI B., TERRITO M. Cutaneous Complications in:
Manual of clinical oncology , Wolters Kluwer, Philadelphia, 2017: 29. - 3. GULATTE M. Symptom Management in:
Clinical guide to antineoplastic therapy – a chemotherapy handbook , Oncology Nursing Society, Pittsburgh, Pennsylvania, 2014:13. - 4. BOERS-DOETS C.B.
How to measure the impact of dermatologic and mucosal adverse events on symptom burden and quality of life , The Asco Post, 2013,http://www.ascopost.com/issues/december-15-2013/how-to-measure-the-impact-of-dermatologicand-mucosal-adverse-events-on-symptom-burden-and-quality-of-life/?utm_source=TrendMD&utm_medium=cpc&utm_campaign=The_ASCO_Post_TrendMD_0 [accessed December 2017]. - 5. NATIONAL CANCER INSTITUTE – DIVISION OF CANCER TREATMENT AND DIAGNOSIS,
Cancer therapy evaluation program ,https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm [accessed December 2017]. - 6. FINLAY AY, KHAN GK.
Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clinical and Experimental Dermatology. 1994;19 (3):201-6. - 7. DEPARTMENT OF DERMATOLOGY, QUALITY OF LIFE QUESTIONNAIRES, CARDIFF UNIVERSITY,
http://sites.cardiffac.uk/dermatology/quality-of-life/dermatology-quality-of-life-index-dlqi/ . [accessed December 2017]. - 8. HOFHEINZ RD, DEPLANQUE G, KOMATSU Y, KOBAYASHI Y, OCVIRK J, RACCA P
et al. Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhbitors in patients with solid tumors , The Oncologist. 2016;21 :1-9. - 9. LACOUTURE ME.
Skin conditions can have severe impact in cancer patients, Oncology, 2011,http://www.practiceupdate.com/content/skin-conditions-can-have-severe-impact-in-cancer-patients/13155/62?trendmd-shared=1 [accessed December 2017]. - 10. PEREZ-SOLER R, CHACHOUA A, HAMMOND LA, ROWINSKY EK, HUBERMAN M, KARP D,
et al. Determinants of tumor response and survival with erlotinib in patients with non small cell lung cancer , J Clin Oncol. 2004;22 (16):3238-47. - 11. VAN CUTSEM E, TEIPAR S, VANBECKEVOORT D, PEETERS M, HUMBLET Y, GELDERBLOM
H et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study , J Clin Oncol. 2012;30 (23):2861-8. - 12. PINTO C, DI FABIO F, ROSATI G, LOLLI IR, RUGGERI EM, CIUFFREDA L,
et al. Observational study on quality of life, safety and effectiveness of first line cetuximab plus chemotherapy in KRAS wild type metastatic colorectal cancer patients: the Observ Er Study. Cancer Med. 2016;5 (11):3272-81.
Language: English
Page range: 96 - 101
Submitted on: Jan 1, 2018
Published on: May 17, 2018
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2018 Maria Alexandra Barbu, Cornelia Niţipir, Theodor Voiosu, Călin Giurcăneanu, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.